What is the current market size and future outlook for the pediatric growth hormone deficiency market?
The pediatric growth hormone deficiency market size has grown strongly in recent years. It will grow from $3.80 billion in 2024 to $4.16 billion in 2025 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to increased awareness regarding the treatment of pediatric growth disorders, increased diagnostic capabilities, a rise in investments in research and development of next-gen products, and a strengthened public insurance scheme.
The pediatric growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to growing healthcare infrastructure and access to care, advancement in growth hormone therapies, heightened awareness and patient advocacy, supportive government policies and healthcare initiatives, and increasing prevalence of PGHD. Major trends in the forecast period include the development of novel therapies, personalized treatment options, product innovation, telemedicine and remote monitoring, and personalized medicine and genetic testing.
Get Your Free Sample of The Global Pediatric Growth Hormone Deficiency Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21250&type=smp
How has the pediatric growth hormone deficiency market evolved, and what factors have shaped its growth?
An increasing prevalence of pediatric diseases is expected to propel the growth of the pediatric growth hormone deficiency market going forward. Pediatric diseases refer to medical conditions or illnesses that primarily affect children, ranging from infancy to adolescence. The increase in pediatric diseases is largely due to environmental factors, better detection methods, lifestyle changes, genetic predispositions, and rising rates of chronic conditions and allergies among children. Pediatric diseases can contribute to pediatric growth hormone deficiency (GHD) by affecting the hypothalamus or pituitary gland, which are responsible for producing growth hormone. For instance, in March 2024, according to the United Nations Children’s Fund (UNICEF), a US-based government organization, in 2022, approximately 4.9 million children under the age of five lost their lives, averaging 13,400 deaths per day. Globally, leading causes of under-five mortality included infectious diseases such as pneumonia, diarrhea, and malaria, as well as complications from preterm birth and intrapartum-related issues. Therefore, the increasing prevalence of pediatric diseases is driving the growth of the pediatric growth hormone deficiency market.
What are the major segments of the pediatric growth hormone deficiency market?
The pediatric growth hormone deficiency market covered in this report is segmented –
1) By Type: Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH deficiency
2) By Product: Recombinant Human Growth Hormone (rhGH), Human Growth Hormone (HGH) Analogs, Long-Acting Growth Hormones
3) By Route Of Administration: Subcutaneous, Intramuscular, Oral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader Willi Syndrome, Other Applications
Subsegments:
1) By Congenital GH Deficiency: Isolated GH Deficiency, Combined Pituitary Hormone Deficiency
2) By Acquired GH Deficiency: GH Deficiency Due To Pituitary Tumors, GH Deficiency Due To Brain Injury, GH Deficiency Due To Radiation Therapy
3) By Idiopathic GH Deficiency: Primary Idiopathic GH Deficiency, Secondary Idiopathic GH Deficiency
Order your report now for swift delivery
Which companies dominate the pediatric growth hormone deficiency market?
Major companies operating in the pediatric growth hormone deficiency market are Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech Inc., Merck KGaA Darmstadt Germany, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., I-Mab Biopharma Co. Ltd., Ipsen Pharma, Gedeon Richter Plc, Ferring Pharmaceuticals, Celltrion Healthcare Co. Ltd., OPKO Health Inc., Zhejiang Hisun Pharmaceutical Co., Ltd., Dong-A ST Co. Ltd., Ascendis Pharma A/S, AnkeBio, Versartis Inc., Changchun Changsheng Life Sciences Ltd.
How will evolving trends contribute to the growth of the pediatric growth hormone deficiency market?
Major companies operating in the pediatric growth hormone deficiency market are focusing on developing innovative solutions, such as long-acting, once-weekly human growth hormone analogs, to improve patient compliance and convenience. A long-acting, once-weekly human growth hormone (HGH) analog refers to a modified version of the natural human growth hormone that has been engineered to have a longer duration of action in the body. For example, in June 2023, Pfizer Inc., a US-based pharmaceutical company, and OPKO Health Inc., a US-based medication company, jointly announced NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog for treating pediatric patients aged three years and older with growth failure due to inadequate secretion of endogenous growth hormone approved by the Food and Drug Administration, a US-based government agency. This innovative therapy aims to improve patient compliance by reducing the frequency of injections, as traditional treatments typically require daily doses. Clinical trials have shown that NGENLA delivers similar efficacy to daily growth hormone treatments, offering a more convenient and manageable option for children and their families.
What are the key regional dynamics of the pediatric growth hormone deficiency market, and which region leads in market share?
North America was the largest region in the pediatric growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pediatric growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Pediatric Growth Hormone Deficiency Market Report 2025 Offer?
The pediatric growth hormone deficiency market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Pediatric growth hormone deficiency (PGHD) is a condition where the pituitary gland produces insufficient growth hormone, leading to slow growth, short stature, and delayed puberty. It can be congenital or acquired, and treatment typically involves recombinant human growth hormone (rhGH) therapy to support normal development.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21250
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
